Deciphering the response and resistance to immunecheckpoint inhibitors in lung cancer with artificial intelligence-based analysis: the pioneer and quantic joint-projects
BENZEKRY, Sébastien
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
BARLESI, Fabrice
Centre de Recherche en Cancérologie de Marseille [CRCM]
Institut Gustave Roussy [IGR]
Direction de la recherche clinique [Gustave Roussy]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Institut Gustave Roussy [IGR]
Direction de la recherche clinique [Gustave Roussy]
BENZEKRY, Sébastien
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
BARLESI, Fabrice
Centre de Recherche en Cancérologie de Marseille [CRCM]
Institut Gustave Roussy [IGR]
Direction de la recherche clinique [Gustave Roussy]
< Réduire
Centre de Recherche en Cancérologie de Marseille [CRCM]
Institut Gustave Roussy [IGR]
Direction de la recherche clinique [Gustave Roussy]
Langue
en
Article de revue
Ce document a été publié dans
British Journal of Cancer. 2020-08, vol. 123, n° 3, p. 337-338
Cancer Research UK
Résumé en anglais
Despite striking results, clinical outcome with immune checkpoint inhibitors remains too often uncertain. This joint-project aims at generating dense longitudinal data in lung cancer patients undergoing anti-PD1 or anti-PDL1 ...Lire la suite >
Despite striking results, clinical outcome with immune checkpoint inhibitors remains too often uncertain. This joint-project aims at generating dense longitudinal data in lung cancer patients undergoing anti-PD1 or anti-PDL1 therapy, alone or in combination with other anticancer agents. Mathematical modelling with mechanistic learning algorithms will be used next to decipher the mechanisms underlying response or resistance to immunotherapy. Ultimately, this project should help to better understand the mechanisms underlying resistance to immune checkpoint inhibitors and identify a serial of actionable items to increase the efficacy of immunotherapy.< Réduire
Project ANR
Precision Immuno-Oncology for advanced Non small cell lung cancer patients with PD-1 ICI Resistance - ANR-17-RHUS-0007
Origine
Importé de halUnités de recherche